These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24367702)

  • 1. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.
    Wei H; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai M; Hellstrom I; Hellstrom KE; Guo Y
    PLoS One; 2013; 8(12):e84927. PubMed ID: 24367702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Regression and Cure Depends on Sustained Th1 Responses.
    Dai M; Hellstrom I; Yip YY; Sjögren HO; Hellstrom KE
    J Immunother; 2018 Oct; 41(8):369-378. PubMed ID: 29912725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response.
    Hellstrom KE; Dai M; Hellstrom I
    Hum Antibodies; 2017; 25(3-4):147-153. PubMed ID: 28085017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
    Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.
    Rodríguez-Ruiz ME; Rodríguez I; Mayorga L; Labiano T; Barbes B; Etxeberria I; Ponz-Sarvise M; Azpilikueta A; Bolaños E; Sanmamed MF; Berraondo P; Calvo FA; Barcelos-Hoff MH; Perez-Gracia JL; Melero I
    Mol Cancer Ther; 2019 Mar; 18(3):621-631. PubMed ID: 30683810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
    Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
    Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
    Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
    Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.
    Eguren-Santamaría I; Rodríguez I; Herrero-Martin C; Fernández de Piérola E; Azpilikueta A; Sánchez-Gregorio S; Bolaños E; Gomis G; Molero-Glez P; Chacón E; Mínguez JÁ; Chiva S; Diez-Caballero F; de Andrea C; Teijeira Á; Sanmamed MF; Melero I
    Oncoimmunology; 2024; 13(1):2373519. PubMed ID: 38988823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
    Dai M; Yip YY; Hellstrom I; Hellstrom KE
    Clin Cancer Res; 2015 Mar; 21(5):1127-38. PubMed ID: 25142145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
    Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
    Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.
    Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A
    Cancer Immunol Immunother; 2018 May; 67(5):815-824. PubMed ID: 29487979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.